PMID- 38292938
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240201
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 15
DP  - 2024
TI  - Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary 
      thyroid cancer: a literature review.
PG  - 1323083
LID - 10.3389/fphar.2024.1323083 [doi]
LID - 1323083
AB  - In the realm of clinical management, Papillary Thyroid Cancer (PTC) stands out as 
      a prevalent thyroid malignancy, characterized by significant metabolic 
      challenges, particularly in the context of carbohydrate metabolism. Recent 
      studies have unveiled promising applications of Dipeptidyl Peptidase-IV (DPP-IV) 
      and Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors, which are conventionally 
      employed in the treatment of type 2 diabetes mellitus (T2DM), as potential 
      adjuncts in anticancer therapy. DPP-IV and SGLT2 inhibitors can be imply to 
      counteract the Warburg effect in cancer, with a specific focus on PTC, owing to 
      their potential metabolic advantages and their influence on the tumor 
      microenvironment, achieved by imposing restrictions on glucose accessibility. 
      Consequently, a comprehensive review has been undertaken, involving meticulous 
      examination of the existing body of evidence pertaining to the utilization of 
      DPP-IV and SGLT2 inhibitors in the context of PTC. The mechanisms of action 
      inherent to these inhibitors have been thoroughly explored, drawing upon insights 
      derived from preclinical investigations. Furthermore, this review initiates 
      discussions concerning the implications for future research directions and the 
      formulation of innovative therapeutic strategies for PTC. As the intricate 
      interplay between carbohydrate metabolism, the Warburg effect, and cancer 
      progression garners increasing attention, attaining a comprehensive understanding 
      of the roles played by DPP-IV and SGLT2 inhibitors in PTC management may serve as 
      the cornerstone for novel approaches aimed at enhancing patient care and 
      broadening the spectrum of available therapeutic modalities.
CI  - Copyright (c) 2024 Buczynska, Kosciuszko, Kretowski and Poplawska-Kita.
FAU - Buczynska, Angelika
AU  - Buczynska A
AD  - Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.
FAU - Kosciuszko, Maria
AU  - Kosciuszko M
AD  - Department of Endocrinology, Diabetology and Internal Medicine, Medical 
      University of Bialystok, Bialystok, Poland.
FAU - Kretowski, Adam Jacek
AU  - Kretowski AJ
AD  - Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.
AD  - Department of Endocrinology, Diabetology and Internal Medicine, Medical 
      University of Bialystok, Bialystok, Poland.
FAU - Poplawska-Kita, Anna
AU  - Poplawska-Kita A
AD  - Department of Endocrinology, Diabetology and Internal Medicine, Medical 
      University of Bialystok, Bialystok, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240116
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10824900
OTO - NOTNLM
OT  - DPP-IV
OT  - Isglt2
OT  - adjuvant therapy
OT  - papillary thyroid cancer
OT  - thyroid cancer
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/01/31 06:42
MHDA- 2024/01/31 06:43
PMCR- 2024/01/16
CRDT- 2024/01/31 04:18
PHST- 2023/10/17 00:00 [received]
PHST- 2024/01/02 00:00 [accepted]
PHST- 2024/01/31 06:43 [medline]
PHST- 2024/01/31 06:42 [pubmed]
PHST- 2024/01/31 04:18 [entrez]
PHST- 2024/01/16 00:00 [pmc-release]
AID - 1323083 [pii]
AID - 10.3389/fphar.2024.1323083 [doi]
PST - epublish
SO  - Front Pharmacol. 2024 Jan 16;15:1323083. doi: 10.3389/fphar.2024.1323083. 
      eCollection 2024.